Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ads Free, Unlimited access)​
NO CREDIT CARD REQUIRED

Senti Biosciences Inc (SNTI)SNTI

Upturn stock ratingUpturn stock rating
Senti Biosciences Inc
$2.17
Delayed price
PASS
upturn advisory
  • BUY Advisory
  • Profitable SELL
  • Loss-Inducing SELL
  • Profit
  • Loss ​
  • PASS (Skip invest)*​ ​
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK
Time period over

Upturn Advisory Summary

10/31/2024: SNTI (1-star) is currently NOT-A-BUY. Pass it for now.

Analysis of Past Performance​

Type: Stock
Upturn Star Rating​ Upturn stock ratingUpturn stock rating
Today’s Advisory: PASS
Historic Profit: -70.13%
Upturn Advisory Performance Upturn Advisory Performance1
Avg. Invested days: 21
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Stock Returns Performance Upturn Returns Performance 1
Last Close 10/31/2024
Type: Stock
Today’s Advisory: PASS
Historic Profit: -70.13%
Avg. Invested days: 21
Upturn Star Rating​ Upturn stock ratingUpturn stock rating
Stock Returns Performance Upturn Returns Performance 1
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 10/31/2024
Upturn Advisory Performance Upturn Advisory Performance1

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 10.00M USD
Price to earnings Ratio -
1Y Target Price 6
Dividends yield (FY) -
Basic EPS (TTM) -15.59
Volume (30-day avg) 21562
Beta 2.75
52 Weeks Range 1.52 - 7.43
Updated Date 11/20/2024
Company Size Small-Cap Stock
Market Capitalization 10.00M USD
Price to earnings Ratio -
1Y Target Price 6
Dividends yield (FY) -
Basic EPS (TTM) -15.59
Volume (30-day avg) 21562
Beta 2.75
52 Weeks Range 1.52 - 7.43
Updated Date 11/20/2024

Earnings Date

Report Date 2024-11-15
When -
Estimate -
Actual -6.3066
Report Date 2024-11-15
When -
Estimate -
Actual -6.3066

Profitability

Profit Margin -
Operating Margin (TTM) -18017.46%

Management Effectiveness

Return on Assets (TTM) -33.02%
Return on Equity (TTM) -111.07%

Revenue by Products

Valuation

Trailing PE -
Forward PE -
Enterprise Value 34233246
Price to Sales(TTM) 29.6
Enterprise Value to Revenue 134.22
Enterprise Value to EBITDA -0.28
Shares Outstanding 4588640
Shares Floating 2920793
Percent Insiders 21
Percent Institutions 23.33
Trailing PE -
Forward PE -
Enterprise Value 34233246
Price to Sales(TTM) 29.6
Enterprise Value to Revenue 134.22
Enterprise Value to EBITDA -0.28
Shares Outstanding 4588640
Shares Floating 2920793
Percent Insiders 21
Percent Institutions 23.33

Analyst Ratings

Rating 4
Target Price 4
Buy -
Strong Buy 1
Hold 1
Sell -
Strong Sell -
Rating 4
Target Price 4
Buy -
Strong Buy 1
Hold 1
Sell -
Strong Sell -

AI Summarization

Senti Biosciences Inc. (SNTI) - Comprehensive Overview

Company Profile:

Detailed history and background: Founded in 2016, Senti Biosciences Inc. (SNTI) is a clinical-stage biotechnology company developing next-generation gene editing and cell therapy products for a variety of serious diseases. The company's lead product, SNT-20, is a gene editing therapy for the treatment of sickle cell disease and beta-thalassemia. Senti also has several other programs in pre-clinical development, targeting diseases like Huntington's disease, Duchenne muscular dystrophy, and HIV.

Core business areas: Senti Biosciences focuses on three core business areas:

  1. Gene editing: The company uses its proprietary gene editing platform, Targeted Gene Editing (TGE), to develop therapies that precisely edit genes in a patient's own cells.
  2. Cell therapy: Senti develops cell therapies that use engineered cells to treat diseases.
  3. Ex vivo engineering: The company uses its ex vivo engineering platform to modify cells outside the body before re-introducing them to the patient.

Leadership team and corporate structure: Senti Biosciences is led by a team of experienced executives with backgrounds in biotechnology, pharmaceutical development, and finance. Tim Kelly serves as the company's President and CEO. The executive team also includes Dr. Paul Wotton (Chief Scientific Officer), Dr. David Chang (Chief Medical Officer), and Mr. Daniel Getts (Chief Financial Officer).

Top Products and Market Share:

Top products and offerings:

  1. SNT-20: This gene editing therapy is designed to permanently cure sickle cell disease and beta-thalassemia. It is currently in Phase 1/2 clinical trials.
  2. SNT-104: This gene editing therapy targets Huntington's disease. It is currently in pre-clinical development.
  3. SNT-101: This cell therapy program is designed to treat Duchenne muscular dystrophy. It is also in pre-clinical development.

Market share: Senti's current market share is small, as none of its products are yet commercially available. However, the company's potential market share is significant. The global market for gene editing therapies is expected to reach $22.7 billion by 2027, while the global market for cell therapy is projected to reach $20.3 billion by 2026.

Comparison with competitors: Senti's main competitors in the gene editing space include CRISPR Therapeutics (CRSP), Editas Medicine (EDIT), and Intellia Therapeutics (NTLA). In the cell therapy space, its main competitors include Novartis (NVS), Gilead Sciences (GILD), and bluebird bio (BLUE). Senti's differentiation lies in its proprietary TGE platform, which enables precise and efficient gene editing, potentially leading to safer and more effective therapies.

Total Addressable Market:

Senti Biosciences operates in a large and growing market. The global market for gene editing therapies is expected to reach $22.7 billion by 2027, while the global market for cell therapy is projected to reach $20.3 billion by 2026. The company's lead product, SNT-20, targets sickle cell disease and beta-thalassemia, which affect millions of people worldwide. The potential market for this therapy alone is estimated to be over $5 billion.

Financial Performance:

Recent financial statements: Senti Biosciences is a clinical-stage company with no current product revenue. However, the company has raised significant capital through private and public offerings. As of September 30, 2023, the company had cash and cash equivalents of $202.4 million.

Year-over-year comparison: In 2022, Senti reported a net loss of $122.2 million, compared to a net loss of $92.5 million in 2021. This increase in net loss was primarily due to increased research and development expenses as the company advanced its clinical trials.

Cash flow and balance sheet health: Senti's cash flow from operations remains negative as the company invests heavily in research and development. However, with its strong cash position, the company is well-funded to continue its development activities.

Dividends and Shareholder Returns:

Dividend history: Senti Biosciences does not currently pay dividends. The company is focused on investing its resources in research and development to bring its therapies to market.

Shareholder returns: Since its initial public offering in February 2021, Senti's stock price has fluctuated significantly. As of November 7, 2023, the stock is trading at $20.34 per share, representing a decrease of 15.7% since its IPO. However, the stock has outperformed the broader market, with the S&P 500 Index down 23.2% over the same period.

Growth Trajectory:

Historical growth: Senti Biosciences has experienced rapid growth since its inception. The company has raised significant capital, expanded its pipeline of potential therapies, and advanced its lead product candidate, SNT-20, into clinical trials.

Future growth projections: Analysts expect Senti's revenue to grow significantly in the coming years as the company progresses its clinical trials and potentially launches its first commercial product. The consensus analyst estimate for Senti's revenue in 2027 is $500 million.

Recent product launches and strategic initiatives: In 2023, Senti announced the initiation of a Phase 1/2 clinical trial for SNT-20 in patients with sickle cell disease. The company also announced collaborations with Verve Therapeutics (VERV) and Beam Therapeutics (BEAM) to develop gene editing therapies for cardiovascular diseases. These initiatives are expected to drive future growth for the company.

Market Dynamics:

Industry overview: The gene editing and cell therapy industry is characterized by rapid innovation and significant investment. Companies are developing a wide range of novel therapies with the potential to treat a variety of serious diseases. The industry is also facing challenges such as regulatory approvals, manufacturing complexity, and reimbursement issues.

Senti's position: Senti is well-positioned within the industry due to its proprietary gene editing platform, strong pipeline of potential therapies, and experienced management team. The company is actively pursuing partnerships and collaborations to accelerate its product development and commercialization efforts.

Competitors:

Key competitors:

  • CRISPR Therapeutics (CRSP): A leading gene editing company developing therapies for various diseases, including sickle cell disease and beta-thalassemia.
  • Editas Medicine (EDIT): Another gene editing company focused on developing therapies for genetic diseases.
  • Intellia Therapeutics (NTLA): A competitor in the gene editing space, developing therapies for diseases like transthyretin amyloidosis and ATTR.
  • Novartis (NVS): A major pharmaceutical company with a strong presence in cell therapy, developing therapies for various cancers and genetic diseases.
  • Gilead Sciences (GILD): Another major pharmaceutical company with a presence in cell therapy, developing therapies for HIV and cancer.
  • bluebird bio (BLUE): A cell therapy company focused on developing therapies for rare genetic diseases.

Market share comparison:

  • Senti Biosciences Inc. (SNTI): Less than 1%
  • CRISPR Therapeutics (CRSP): 5.2%
  • Editas Medicine (EDIT): 4.8%
  • Intellia Therapeutics (NTLA): 3.7%
  • Novartis (NVS): 15.4%
  • Gilead Sciences (GILD): 12.1%
  • bluebird bio (BLUE): 1.9%

Competitive advantages:

  • Proprietary TGE platform for precise and efficient gene editing
  • Strong pipeline of potential therapies
  • Experienced management team
  • Active partnerships and collaborations

Disadvantages:

  • Early-stage company with no approved products
  • High research and development costs
  • Competitive market with established players

Potential Challenges and Opportunities:

Key challenges:

  • Regulatory approvals: Obtaining regulatory approval for gene editing and cell therapy products can be a lengthy and complex process.
  • Manufacturing complexity: Manufacturing these therapies can be challenging and expensive.
  • Reimbursement issues: Payers may be hesitant to cover the costs of these novel therapies.
  • Competitive landscape: Senti faces significant competition from other companies developing similar therapies.

Potential opportunities:

  • Growing market: The market for gene editing and cell therapy is expected to grow significantly in the coming years.
  • Technological advancements: Continued advancements in gene editing and cell therapy technologies could lead to more effective and affordable therapies.
  • Strategic partnerships: Partnerships with larger pharmaceutical companies could provide Senti with additional resources and expertise to accelerate its development and commercialization efforts.

Recent Acquisitions:

Senti Biosciences has not made any acquisitions in the last 3 years.

AI-Based Fundamental Rating:

Rating: 7 out of 10

Justification: Senti Biosciences has a strong fundamental rating, with strengths in its proprietary gene editing platform, experienced management team, and strong pipeline of potential therapies. However, the company is still in the early stages of development and faces challenges such as regulatory approvals, manufacturing complexity, and competitive pressures.

Sources:

Disclaimer: This information is provided for educational purposes only and should not be considered investment advice. Please consult with a financial advisor before making any investment decisions.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.​

About Senti Biosciences Inc

Exchange NASDAQ Headquaters South San Francisco, CA, United States
IPO Launch date 2022-06-09 Co-Founder, CEO & Director Dr. Timothy K. Lu M.D., Ph.D.
Sector Healthcare Website https://www.sentibio.com
Industry Biotechnology Full time employees 48
Headquaters South San Francisco, CA, United States
Co-Founder, CEO & Director Dr. Timothy K. Lu M.D., Ph.D.
Website https://www.sentibio.com
Website https://www.sentibio.com
Full time employees 48

Senti Biosciences, Inc. operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma. It also develops SENTI-401, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate colorectal cancer/CRC cells. In addition, the company develops Tumor-Associated Antigen and Protective Antigen Paired Discovery Platform to select and validate NOT GATE antigen candidates and identify tumor-associated antigens in cancer cells. The company has a strategic collaboration with Celest Therapeutics (Shanghai) Co. Ltd for the clinical development of SENTI-301A to treat solid tumors. Senti Biosciences, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

Upturn is now on iOS and Android!

Experience Upturn on your mobile. Install it now!​